Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
CKD-330 Phase 3 Trial in Amlodipine Non-responder
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 160
- Registration Number
- NCT02586311
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Drug: Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mgDrug: CKD-395 0.5/1000mg
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2015-10-01
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 26
- Registration Number
- NCT02565368
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju-si, Jeollabuk-do, Korea, Republic of
Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 53
- Registration Number
- NCT02548286
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of
Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled
Phase 4
- Conditions
- Hypertension
- Interventions
- Drug: Telminuvo®Tab. 40/2.5mg
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 208
- Registration Number
- NCT02526875
- Locations
- 🇰🇷
Keimyung University Dongsan Medical Center, Daegu, Gyeongsangbuk-do, Korea, Republic of
🇰🇷Myongji Hospital, Goyang, Gyeonggi-di, Korea, Republic of
🇰🇷Korean University Guro Hospital, Seoul, Guro-gu, Korea, Republic of
CKD-391 Pharmacokinetic Study Phase I
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Atrovastatin and Ezetimibe combination therapy
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2016-12-26
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 46
- Registration Number
- NCT02501200
Clinical Trial to Evaluate the Efficacy and Safety of CKD-342
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2016-12-26
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 459
- Registration Number
- NCT02498509
- Locations
- 🇰🇷
Samsung Medical Center, Irwon-dong, Gangnam-gu, Seoul, Korea, Republic of
Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI)
Phase 1
Completed
- Conditions
- Dyslipidemia
- Interventions
- Drug: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 45
- Registration Number
- NCT02484482
- Locations
- 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of
Efficacy and Safety of Lobeglitazone Versus Sitagliptin
Phase 4
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Lobelitazone 0.5mg
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 248
- Registration Number
- NCT02480465
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
CKD-391 Pharmacokinetic Study
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Atrovastatin and Ezetimibe combination therapy
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 52
- Registration Number
- NCT02461004
- Locations
- 🇰🇷
The Korea University Anam Hospital, Seoul, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of CKD-391
Phase 3
Completed
- Conditions
- Hyperlipidemia
- Interventions
- Drug: Atorvastatin10mg, Ezetimibe10mgDrug: Atorvastatin20mg, Ezetimibe10mgDrug: Atorvastatin40mg, Ezetimibe10mg
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2016-01-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 385
- Registration Number
- NCT02451098
- Locations
- 🇰🇷
The catholic university of korea seoul st. Mary's hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath